Market Research Logo

Fibrosis - Pipeline Review, H1 2015

Fibrosis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Fibrosis - Pipeline Review, H1 2015’, provides an overview of the Fibrosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Fibrosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Fibrosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Fibrosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Fibrosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Fibrosis Overview
Therapeutics Development
Pipeline Products for Fibrosis - Overview
Pipeline Products for Fibrosis - Comparative Analysis
Fibrosis - Therapeutics under Development by Companies
Fibrosis - Therapeutics under Investigation by Universities/Institutes
Fibrosis - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Fibrosis - Products under Development by Companies
Fibrosis - Products under Investigation by Universities/Institutes
Fibrosis - Companies Involved in Therapeutics Development
Acceleron Pharma, Inc.
AiCuris GmbH & Co. KG
AnaMar AB
Arena Pharmaceuticals, Inc.
Bristol-Myers Squibb Company
Digna Biotech, S.L.
F. Hoffmann-La Roche Ltd.
FibroGen, Inc.
Five Prime Therapeutics, Inc.
Galectin Therapeutics, Inc.
GenKyoTex S.A.
GlycoMimetics, Inc.
HanAll Biopharma Co., Ltd.
Intercept Pharmaceuticals, Inc.
Isarna Therapeutics GmbH
KineMed, Inc.
Lycera Corp.
MandalMed, Inc.
miRagen Therapeutics, Inc.
Neumedicines Inc.
Pfizer Inc.
Promedior, Inc.
ProMetic Life Sciences Inc.
RuiYi Inc.
Scholar Rock, Inc.
Siena Biotech S.p.A.
SK Chemicals Co., Ltd.
Taisho Pharmaceutical Co., Ltd.
TRACON Pharmaceuticals, Inc.
UCB S.A.
Vericel Corporation
VivaCell Biotechnology Espana S.L.
Fibrosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AIC-649 - Drug Profile
AMAP-102 - Drug Profile
Antibodies for Fibrosis - Drug Profile
Antibody to Inhibit Transglutaminase 2 for Fibrosis - Drug Profile
APD-371 - Drug Profile
ASPH-0047 - Drug Profile
ASPH-1047 - Drug Profile
Biologics to Inhibit TGF-beta 1 for Fibrosis - Drug Profile
disitertide - Drug Profile
Drug to Modulate Galectin for Fibrosis, Inflammation and Cancer - Drug Profile
G-XXX - Drug Profile
Galectin-3C - Drug Profile
GC-4419 - Drug Profile
GKT-136901 - Drug Profile
HL-156FIB - Drug Profile
INT-767 - Drug Profile
ixmyelocel-T - Drug Profile
KBP-7018 - Drug Profile
MGN-4220 - Drug Profile
NCE-401 - Drug Profile
NMIL-121 - Drug Profile
noscapine - Drug Profile
NPH-09 - Drug Profile
P-006 - Drug Profile
PBI-4419 - Drug Profile
PF-06473871 - Drug Profile
Polysaccharides to Inhibit Galectin for Fibrosis, Inflammation and Cancer - Drug Profile
PRI-724 - Drug Profile
PRM-151 - Drug Profile
Protein for Fibrosis - Drug Profile
Proteins for Fibrosis - Drug Profile
Recombinant Protein to Inhibit BMP-1 like Proteinases for Fibrotic Disorders - Drug Profile
RYI-018 - Drug Profile
Small molecule for cancer and fibrotic disease - Drug Profile
Small Molecule for Fibrotic Diseases - Drug Profile
Small Molecule to Antagonize 5-HT2 Receptor for Cardiovascular, Inflammation, Inflammatory Pain and Fibrosis - Drug Profile
Small Molecule to Antagonize CCR2 and CCR5 for Fibrotic Diseases - Drug Profile
Small Molecule to Inhibit ALK5 for Alopecia and Fibrosis - Drug Profile
Small Molecule to Inhibit Galectin-3 for Fibrosis, Cancer and Cardiovascular Disease - Drug Profile
Small Molecule to Inhibit LOXL2 for Fibrosis - Drug Profile
Small Molecule to Inhibit Rho Kinase for Fibrosis - Drug Profile
Small Molecule to Inhibit Tankyrase/Wnt for Musculoskeletal, CNS and Oncology - Drug Profile
Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis - Drug Profile
Small Molecules to Antagonize S1P3 for Inflammation, Neurodegenerative Diseases and Fibrosis - Drug Profile
Small Molecules to Inhibit Procollagen C-Proteinase for Fibrosis - Drug Profile
Small Molecules to Inhibit SMURF2 for Fibrosis, Oncology and IBD - Drug Profile
Small Molecules to Inhibit SphK1 for Oncology, Autoimmune Disorders, Fibrosis and Neurodegenerative Diseases - Drug Profile
SphK2 Program - Drug Profile
TRC-205 - Drug Profile
Trophokine - Drug Profile
VCE-0048 - Drug Profile
Fibrosis - Recent Pipeline Updates
Fibrosis - Dormant Projects
Fibrosis - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Fibrosis, H1 2015
Number of Products under Development for Fibrosis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2015
Fibrosis - Pipeline by Acceleron Pharma, Inc., H1 2015
Fibrosis - Pipeline by AiCuris GmbH & Co. KG, H1 2015
Fibrosis - Pipeline by AnaMar AB, H1 2015
Fibrosis - Pipeline by Arena Pharmaceuticals, Inc., H1 2015
Fibrosis - Pipeline by Bristol-Myers Squibb Company, H1 2015
Fibrosis - Pipeline by Digna Biotech, S.L., H1 2015
Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Fibrosis - Pipeline by FibroGen, Inc., H1 2015
Fibrosis - Pipeline by Five Prime Therapeutics, Inc., H1 2015
Fibrosis - Pipeline by Galectin Therapeutics, Inc., H1 2015
Fibrosis - Pipeline by GenKyoTex S.A., H1 2015
Fibrosis - Pipeline by GlycoMimetics, Inc., H1 2015
Fibrosis - Pipeline by HanAll Biopharma Co., Ltd., H1 2015
Fibrosis - Pipeline by Intercept Pharmaceuticals, Inc., H1 2015
Fibrosis - Pipeline by Isarna Therapeutics GmbH, H1 2015
Fibrosis - Pipeline by KineMed, Inc., H1 2015
Fibrosis - Pipeline by Lycera Corp., H1 2015
Fibrosis - Pipeline by MandalMed, Inc., H1 2015
Fibrosis - Pipeline by miRagen Therapeutics, Inc., H1 2015
Fibrosis - Pipeline by Neumedicines Inc., H1 2015
Fibrosis - Pipeline by Pfizer Inc., H1 2015
Fibrosis - Pipeline by Promedior, Inc., H1 2015
Fibrosis - Pipeline by ProMetic Life Sciences Inc., H1 2015
Fibrosis - Pipeline by RuiYi Inc., H1 2015
Fibrosis - Pipeline by Scholar Rock, Inc., H1 2015
Fibrosis - Pipeline by Siena Biotech S.p.A., H1 2015
Fibrosis - Pipeline by SK Chemicals Co., Ltd., H1 2015
Fibrosis - Pipeline by Taisho Pharmaceutical Co., Ltd., H1 2015
Fibrosis - Pipeline by TRACON Pharmaceuticals, Inc., H1 2015
Fibrosis - Pipeline by UCB S.A., H1 2015
Fibrosis - Pipeline by Vericel Corporation, H1 2015
Fibrosis - Pipeline by VivaCell Biotechnology Espana S.L., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Fibrosis Therapeutics - Recent Pipeline Updates, H1 2015
Fibrosis - Dormant Projects, H1 2015
Fibrosis - Dormant Projects (Contd..1), H1 2015
Fibrosis - Dormant Projects (Contd..2), H1 2015
Fibrosis - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Fibrosis, H1 2015
Number of Products under Development for Fibrosis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report